This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
ChengLEngCNiemanLZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol2011;34:573–580.
ChengLEngCNiemanLZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol2011;34:573–580.
)| false
SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212–236.
SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212–236.
)| false
BaileyCEHuCYYouYN. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg2014:1–6.
BaileyCEHuCYYouYN. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg2014:1–6.
)| false
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
)| false
BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1284–1292.
BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1284–1292.
)| false
BurokerTRO'ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:14–20.
BurokerTRO'ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:14–20.
)| false
CassidyJClarkeSDiaz-RubioE. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol2008;26:2006–2012.
CassidyJClarkeSDiaz-RubioE. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol2008;26:2006–2012.
)| false
CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393–399.
CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393–399.
)| false
ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol2005;23:4866–4875.
ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol2005;23:4866–4875.
)| false
CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337–345.
CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337–345.
)| false
CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:1413–1418.
CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:1413–1418.
)| false
de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808–815.
de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808–815.
)| false
de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:2938–2947.
de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:2938–2947.
)| false
DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741. Cancer2004;101:2170–2176.
DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741. Cancer2004;101:2170–2176.
)| false
DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:1041–1047.
DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:1041–1047.
)| false
DouillardJYSienaSCassidyJ. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28:4697–4705.
DouillardJYSienaSCassidyJ. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28:4697–4705.
)| false
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
)| false
FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807–814.
FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807–814.
)| false
GiantonioBJCatalanoPJMeropolNJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol2007;25:1539–1544.
GiantonioBJCatalanoPJMeropolNJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol2007;25:1539–1544.
)| false
GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:38–50.
GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:38–50.
)| false
GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:23–30.
GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:23–30.
)| false
HallerDGRothenbergMLWongAO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol2008;26:4544–4550.
HallerDGRothenbergMLWongAO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol2008;26:4544–4550.
)| false
HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:3502–3508.
HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:3502–3508.
)| false
JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:2274–2279.
JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:2274–2279.
)| false
KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:3706–3712.
KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:3706–3712.
)| false
KohneCHHofheinzRMineurL. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol2012;138:65–72.
KohneCHHofheinzRMineurL. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol2012;138:65–72.
)| false
Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:1338–1342.
Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:1338–1342.
)| false
PeetersMPriceTJCervantesA. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol2010;28:4706–4713.
PeetersMPriceTJCervantesA. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol2010;28:4706–4713.
)| false
PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:1559–1565.
PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:1559–1565.
)| false
SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:2013–2019.
SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:2013–2019.
)| false
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer2006;94:798–805.
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer2006;94:798–805.
)| false
Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:1190–1197.
Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:1190–1197.
)| false
Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:1658–1664.
Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:1658–1664.
)| false
Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:4097–4106.
Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:4097–4106.
)| false
Van CutsemETaberneroJLakomyR. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol2012;30:3499–3506.
Van CutsemETaberneroJLakomyR. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol2012;30:3499–3506.
)| false
WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:1879–1887.
WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:1879–1887.
)| false
LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:21–33.
LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:21–33.
)| false
TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229–237.
TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229–237.
)| false
CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:2084–2091.
CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:2084–2091.
)| false
PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:4217–4223.
PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:4217–4223.
)| false
KirsteinMMLangeAPrenzlerA. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist2014;19:1156–1168.
KirsteinMMLangeAPrenzlerA. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist2014;19:1156–1168.
)| false
DucreuxMMalkaDMendiboureJ. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol2011;12:1032–1044.
DucreuxMMalkaDMendiboureJ. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol2011;12:1032–1044.
)| false
KoopmanMAntoniniNFDoumaJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet2007;370:135–142.
KoopmanMAntoniniNFDoumaJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet2007;370:135–142.
)| false
SeymourMTMaughanTSLedermannJA. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;370:143–152.
SeymourMTMaughanTSLedermannJA. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;370:143–152.
)| false
GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:1209–1214.
GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:1209–1214.
)| false
SargentDJKohneCHSanoffHK. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol2009;27:1948–1955.
SargentDJKohneCHSanoffHK. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol2009;27:1948–1955.
)| false
SimkensLHvan TinterenHMayA. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet2015;385:1843–1852.
SimkensLHvan TinterenHMayA. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet2015;385:1843–1852.
)| false
Hegewisch-BeckerSGraevenULerchenmullerCA. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol2015;16:1355–1369.
Hegewisch-BeckerSGraevenULerchenmullerCA. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol2015;16:1355–1369.
)| false
KoeberleDBetticherDCvon MoosR. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol2015;26:709–714.
KoeberleDBetticherDCvon MoosR. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol2015;26:709–714.
)| false
TournigandCChibaudelBSamsonB. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol2015;16:1493–1505.
TournigandCChibaudelBSamsonB. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol2015;16:1493–1505.
)| false
HagmanHFrodinJEBerglundA. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol2016;27:140–147.
HagmanHFrodinJEBerglundA. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol2016;27:140–147.
)| false
XuWGongYKuangM. Survival benefit and safety of bevacizumab in combination with erlotinib as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis. Clin Drug Investig2017;37:155–165.
XuWGongYKuangM. Survival benefit and safety of bevacizumab in combination with erlotinib as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis. Clin Drug Investig2017;37:155–165.
)| false
LuoHYLiYHWangW. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol2016;27:1074–1081.
LuoHYLiYHWangW. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol2016;27:1074–1081.
)| false
HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:2335–2342.
HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:2335–2342.
)| false
KabbinavarFHurwitzHIFehrenbacherL. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol2003;21:60–65.
KabbinavarFHurwitzHIFehrenbacherL. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol2003;21:60–65.
)| false
KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:3697–3705.
KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:3697–3705.
)| false
PetrelliFBorgonovoKCabidduM. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer2013;12:145–151.
PetrelliFBorgonovoKCabidduM. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer2013;12:145–151.
)| false
HurwitzHIBekaii-SaabTSBendellJC. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol)2014;26:323–332.
HurwitzHIBekaii-SaabTSBendellJC. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol)2014;26:323–332.
)| false
Fourrier-ReglatASmithDRouyerM. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol2014;9:311–319.
Fourrier-ReglatASmithDRouyerM. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol2014;9:311–319.
)| false
BotrelTEClarkLGPaladiniLClarkOA. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer2016;16:677.
BotrelTEClarkLGPaladiniLClarkOA. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer2016;16:677.
)| false
CaoYTanAGaoF. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis2009;24:677–685.
CaoYTanAGaoF. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis2009;24:677–685.
)| false
HuWXuWLiaoXHeH. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Minerva Chir2015;70:451–458.
HuWXuWLiaoXHeH. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Minerva Chir2015;70:451–458.
)| false
HurwitzHITebbuttNCKabbinavarF. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist2013;18:1004–1012.
HurwitzHITebbuttNCKabbinavarF. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist2013;18:1004–1012.
)| false
LoupakisFBriaEVaccaroV. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res2010;29:58.
LoupakisFBriaEVaccaroV. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res2010;29:58.
)| false
LvCWuSZhengD. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm2013;28:501–509.
LvCWuSZhengD. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm2013;28:501–509.
)| false
WelchSSpithoffKRumbleRBMarounJ. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol2010;21:1152–1162.
WelchSSpithoffKRumbleRBMarounJ. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol2010;21:1152–1162.
)| false
ZhangGZhouXLinC. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Int J Clin Exp Med2015;8:1434–1445.
ZhangGZhouXLinC. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Int J Clin Exp Med2015;8:1434–1445.
)| false
MacedoLTda Costa LimaABSasseAD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer2012;12:89.
MacedoLTda Costa LimaABSasseAD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer2012;12:89.
)| false
MeyerhardtJALiLSanoffHK. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol2012;30:608–615.
MeyerhardtJALiLSanoffHK. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol2012;30:608–615.
)| false
HartmannHMullerJMarschnerN. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?J Clin Oncol2012;30:3317–3318; author reply 3318.
HartmannHMullerJMarschnerN. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?J Clin Oncol2012;30:3317–3318; author reply 3318.
)| false
HurwitzHILymanGH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?J Clin Oncol2012;30:580–581.
HurwitzHILymanGH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?J Clin Oncol2012;30:580–581.
)| false
AllegraCJYothersGO'ConnellMJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol2011;29:11–16.
AllegraCJYothersGO'ConnellMJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol2011;29:11–16.
)| false
de GramontAVan CutsemESchmollHJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol2012;13:1225–1233.
de GramontAVan CutsemESchmollHJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol2012;13:1225–1233.
)| false
HurwitzHISaltzLBVan CutsemE. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol2011;29:1757–1764.
HurwitzHISaltzLBVan CutsemE. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol2011;29:1757–1764.
)| false
DaiFShuLBianY. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig2013;33:779–788.
DaiFShuLBianY. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig2013;33:779–788.
)| false
HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol2008;26:3523–3529.
HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol2008;26:3523–3529.
)| false
CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:5180–5186.
CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:5180–5186.
)| false
GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830–1835.
GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830–1835.
)| false
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–9106.
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–9106.
)| false
MilesDHarbeckNEscudierB. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol2011;29:83–88.
MilesDHarbeckNEscudierB. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol2011;29:83–88.
)| false
PotemskiP. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?J Clin Oncol2011;29:e384–385.
PotemskiP. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?J Clin Oncol2011;29:e384–385.
)| false
SorichMJWieseMDRowlandA. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol2015;26:13–21.
SorichMJWieseMDRowlandA. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol2015;26:13–21.
)| false
HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963–964.
HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963–964.
)| false
HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529–531.
HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529–531.
)| false
ReschGSchaberl-MoserRKierP. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol2011;22:486–487.
ReschGSchaberl-MoserRKierP. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol2011;22:486–487.
)| false
LievreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
LievreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
)| false
PetrelliFBorgonovoKBarniS. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol2013;8:173–181.
PetrelliFBorgonovoKBarniS. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol2013;8:173–181.
)| false
StintzingSKapaunCLaubenderRP. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer2013;132:236–245.
StintzingSKapaunCLaubenderRP. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer2013;132:236–245.
)| false
Van CutsemETejparSVanbeckevoortD. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol2012;30:2861–2868.
Van CutsemETejparSVanbeckevoortD. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol2012;30:2861–2868.
)| false
BurtnessBAnadkatMBastiS. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw2009;7(Suppl 1):S5–21; quiz S22–24.
BurtnessBAnadkatMBastiS. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw2009;7(Suppl 1):S5–21; quiz S22–24.
)| false
PetrelliFCabidduMBorgonovoKBarniS. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol2012;23:1672–1679.
PetrelliFCabidduMBorgonovoKBarniS. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol2012;23:1672–1679.
)| false
ZhangDYeJXuTXiongB. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother2013;25:170–175.
ZhangDYeJXuTXiongB. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother2013;25:170–175.
)| false
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
)| false
BruleSYJonkerDJKarapetisCS. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer2015;51:1405–1414.
BruleSYJonkerDJKarapetisCS. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer2015;51:1405–1414.
)| false
MorettoRCremoliniCRossiniD. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist2016;21:988–994.
MorettoRCremoliniCRossiniD. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist2016;21:988–994.
)| false
LoupakisFYangDYauL. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst2015;107:doi: 10.1093/jnci/dju427.
LoupakisFYangDYauL. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst2015;107:doi: 10.1093/jnci/dju427.
)| false
LeeMSAdvaniSMMorrisJ. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3506.
LeeMSAdvaniSMMorrisJ. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3506.
)| false
ChenKHShaoYYChenHM. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer2016;16:327.
ChenKHShaoYYChenHM. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer2016;16:327.
)| false
SchragDWengSBrooksG. The relationship between primary tumor sidedness and prognosis in colorectal cancer [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3505.
SchragDWengSBrooksG. The relationship between primary tumor sidedness and prognosis in colorectal cancer [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3505.
)| false
VenookAPNiedzwieckiDInnocentiF. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3504.
VenookAPNiedzwieckiDInnocentiF. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3504.
)| false
VenookAPNiedzwieckiDInnocentiF. Impact of primary (1°) tumor location on Overall Survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of All RAS wt patients on CALGB / SWOG 80405 (Alliance) [abstract]. Presented at ESMO Congress 2016; October7–112016; Copenhagen, Denmark.
VenookAPNiedzwieckiDInnocentiF. Impact of primary (1°) tumor location on Overall Survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of All RAS wt patients on CALGB / SWOG 80405 (Alliance) [abstract]. Presented at ESMO Congress 2016; October7–11, 2016; Copenhagen, Denmark.
)| false
McKayJAMurrayLJCurranS. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer2002;38:2258–2264.
McKayJAMurrayLJCurranS. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer2002;38:2258–2264.
)| false
YenLCUenYHWuDC. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg2010;251:254–260.
YenLCUenYHWuDC. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg2010;251:254–260.
)| false
HechtJRMitchellENeubauerMA. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res2010;16:2205–2213.
HechtJRMitchellENeubauerMA. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res2010;16:2205–2213.
)| false
SaltzLBMeropolNJLoehrerPJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:1201–1208.
SaltzLBMeropolNJLoehrerPJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:1201–1208.
)| false
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–671.
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–671.
)| false
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
)| false
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
)| false
TejparSCelikISchlichtingM. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol2012;30:3570–3577.
TejparSCelikISchlichtingM. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol2012;30:3570–3577.
)| false
ArtaleSSartore-BianchiAVeroneseSM. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
ArtaleSSartore-BianchiAVeroneseSM. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
)| false
Etienne-GrimaldiMCFormentoJLFrancoualM. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res2008;14:4830–4835.
Etienne-GrimaldiMCFormentoJLFrancoualM. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res2008;14:4830–4835.
)| false
KnijnNMekenkampLJKlompM. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer2011;104:1020–1026.
KnijnNMekenkampLJKlompM. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer2011;104:1020–1026.
)| false
WangHLLopateguiJAminMBPattersonSD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol2010;17:23–32.
WangHLLopateguiJAminMBPattersonSD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol2010;17:23–32.
)| false
MonzonFAOginoSHammondMEH. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med2009;133:1600–1606.
MonzonFAOginoSHammondMEH. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med2009;133:1600–1606.
)| false
RothADTejparSDelorenziM. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol2010;28:466–474.
RothADTejparSDelorenziM. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol2010;28:466–474.
)| false
YoonHHTougeronDShiQ. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res2014;20:3033–3043.
YoonHHTougeronDShiQ. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res2014;20:3033–3043.
)| false
De RoockWJonkerDJDi NicolantonioF. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA2010;304:1812–1820.
De RoockWJonkerDJDi NicolantonioF. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA2010;304:1812–1820.
)| false
PeetersMDouillardJYVan CutsemE. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol2013;31:759–765.
PeetersMDouillardJYVan CutsemE. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol2013;31:759–765.
)| false
SchirripaMLoupakisFLonardiS. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol2015;26:2503.
SchirripaMLoupakisFLonardiS. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol2015;26:2503.
)| false
SegelovEThavaneswaranSWaringPM. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study. J Clin Oncol2016;34:2258–2264.
SegelovEThavaneswaranSWaringPM. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study. J Clin Oncol2016;34:2258–2264.
)| false
PriceTJBruhnMALeeCK. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer2015;112:963–970.
PriceTJBruhnMALeeCK. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer2015;112:963–970.
)| false
HeinemannVvon WeikersthalLFDeckerT. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol2014;15:1065–1075.
HeinemannVvon WeikersthalLFDeckerT. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol2014;15:1065–1075.
)| false
Van CutsemEKohneCHLangI. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol2011;29:2011–2019.
Van CutsemEKohneCHLangI. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol2011;29:2011–2019.
)| false
MaughanTSAdamsRASmithCG. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet2011;377:2103–2114.
MaughanTSAdamsRASmithCG. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet2011;377:2103–2114.
)| false
IkenoueTHikibaYKanaiF. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res2003;63:8132–8137.
IkenoueTHikibaYKanaiF. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res2003;63:8132–8137.
)| false
BokemeyerCCutsemEVRougierP. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer2012;48:1466–1475.
BokemeyerCCutsemEVRougierP. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer2012;48:1466–1475.
)| false
Di NicolantonioFMartiniMMolinariF. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008;26:5705–5712.
Di NicolantonioFMartiniMMolinariF. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008;26:5705–5712.
)| false
Laurent-PuigPCayreAManceauG. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol2009;27:5924–5930.
Laurent-PuigPCayreAManceauG. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol2009;27:5924–5930.
)| false
De RoockWClaesBBernasconiD. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol2010;11:753–762.
De RoockWClaesBBernasconiD. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol2010;11:753–762.
)| false
SeymourMTBrownSRMiddletonG. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol2013;14:749–759.
SeymourMTBrownSRMiddletonG. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol2013;14:749–759.
)| false
PietrantonioFPetrelliFCoinuA. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer2015;51:587–594.
PietrantonioFPetrelliFCoinuA. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer2015;51:587–594.
)| false
RowlandADiasMMWieseMD. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer2015;112:1888–1894.
RowlandADiasMMWieseMD. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer2015;112:1888–1894.
)| false
ChenDHuangJFLiuK. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One2014;9:e90607.
ChenDHuangJFLiuK. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One2014;9:e90607.
)| false
PriceTJHardinghamJELeeCK. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol2011;29:2675–2682.
PriceTJHardinghamJELeeCK. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol2011;29:2675–2682.
)| false
Safaee ArdekaniGJafarnejadSMTanL. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One2012;7:e47054.
Safaee ArdekaniGJafarnejadSMTanL. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One2012;7:e47054.
)| false
SamowitzWSSweeneyCHerrickJ. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res2005;65:6063–6069.
SamowitzWSSweeneyCHerrickJ. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res2005;65:6063–6069.
)| false
XuQXuATZhuMM. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis2013;14:409–416.
XuQXuATZhuMM. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis2013;14:409–416.
)| false
ClancyCBurkeJPKaladyMFCoffeyJC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis2013;15:e711–718.
ClancyCBurkeJPKaladyMFCoffeyJC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis2013;15:e711–718.
)| false
SantiniDSpotoCLoupakisF. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol2010;21:1565.
SantiniDSpotoCLoupakisF. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol2010;21:1565.
)| false
RaghavKPSOvermanMJYuR. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3517.
RaghavKPSOvermanMJYuR. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3517.
)| false
ValtortaEMartinoCSartore-BianchiA. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol2015;28:1481–1491.
ValtortaEMartinoCSartore-BianchiA. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol2015;28:1481–1491.
)| false
HurwitzHHainsworthJDSwantonC. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors [abstract]. J Clin Oncol2016;34(Suppl):Abstract 653.
HurwitzHHainsworthJDSwantonC. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors [abstract]. J Clin Oncol2016;34(Suppl):Abstract 653.
)| false
WuSWMaCCLiWH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol2015;10:144.
WuSWMaCCLiWH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol2015;10:144.
)| false
MartinVLandiLMolinariF. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer2013;108:668–675.
MartinVLandiLMolinariF. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer2013;108:668–675.
)| false
LangIKohneCHFolprechtG. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer2013;49:439–448.
LangIKohneCHFolprechtG. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer2013;49:439–448.
)| false
Van CutsemELenzHJKohneCH. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol2015;33:692–700.
Van CutsemELenzHJKohneCH. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol2015;33:692–700.
)| false
MitchellEPPiperdiBLacoutureME. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer2011;10:333–339.
MitchellEPPiperdiBLacoutureME. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer2011;10:333–339.
)| false
PeetersMPriceTJCervantesA. Final results from a randomized phase 3 study of FOLFIRI {+/–} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol2014;25:107–116.
PeetersMPriceTJCervantesA. Final results from a randomized phase 3 study of FOLFIRI {+/–} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol2014;25:107–116.
)| false
BokemeyerCBondarenkoIHartmannJT. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol2011;22:1535–1546.
BokemeyerCBondarenkoIHartmannJT. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol2011;22:1535–1546.
)| false
TaiebJMaughanTBokemeyerC. Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): a pooled analysis of COIN and OPUS study data [abstract]. J Clin Oncol2012;30(Suppl):Abstract 3574.
TaiebJMaughanTBokemeyerC. Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): a pooled analysis of COIN and OPUS study data [abstract]. J Clin Oncol2012;30(Suppl):Abstract 3574.
)| false
TveitKMGurenTGlimeliusB. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol2012;30:1755–1762.
TveitKMGurenTGlimeliusB. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol2012;30:1755–1762.
)| false
VenookAPNiedzwieckiDLenzHJ. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstract]. J Clin Oncol2014;32(Suppl):Abstract LBA3.
VenookAPNiedzwieckiDLenzHJ. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstract]. J Clin Oncol2014;32(Suppl):Abstract LBA3.
)| false
PrimroseJFalkSFinch-JonesM. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol2014;15:601–611.
PrimroseJFalkSFinch-JonesM. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol2014;15:601–611.
)| false
ModestDPStintzingSvon WeikersthalLF. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol2015;33:3718–3726.
ModestDPStintzingSvon WeikersthalLF. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol2015;33:3718–3726.
)| false
O'NeilBHVenookAP. Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others?J Clin Oncol2015;33:3686–3688.
O'NeilBHVenookAP. Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others?J Clin Oncol2015;33:3686–3688.
)| false
SchwartzbergLSRiveraFKarthausM. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol2014;32:2240–2247.
SchwartzbergLSRiveraFKarthausM. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol2014;32:2240–2247.
)| false
Riesco-MartinezMCBerrySRKoYJ. Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer. J Oncol Pract2016;12:e710–723.
Riesco-MartinezMCBerrySRKoYJ. Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer. J Oncol Pract2016;12:e710–723.
)| false
SchragDDueckACNaughtonMJ. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405 [abstract]. J Clin Oncol2015;33(Suppl):Abstract 6504.
SchragDDueckACNaughtonMJ. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405 [abstract]. J Clin Oncol2015;33(Suppl):Abstract 6504.
)| false
HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:2078–2083.
HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:2078–2083.
)| false
RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:1407–1412.
RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:1407–1412.
)| false
KimGPSargentDJMahoneyMR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol2009;27:2848–2854.
KimGPSargentDJMahoneyMR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol2009;27:2848–2854.
)| false
SegelovEChanDShapiroJ. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer2014;111:1122–1131.
SegelovEChanDShapiroJ. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer2014;111:1122–1131.
)| false
HofheinzRDRonellenfitschUKubickaS. Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials. Gastroenterol Res Pract2016;2016:9189483.
HofheinzRDRonellenfitschUKubickaS. Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials. Gastroenterol Res Pract2016;2016:9189483.
)| false
PeetersMOlinerKPriceTJ. Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res2015;21:5469–5479.
PeetersMOlinerKPriceTJ. Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res2015;21:5469–5479.
)| false
SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:2311–2319.
SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:2311–2319.
)| false
BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol2013;14:29–37.
BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol2013;14:29–37.
)| false
KubickaSGreilRAndreT. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol2013;24:2342–2349.
KubickaSGreilRAndreT. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol2013;24:2342–2349.
)| false
MasiGSalvatoreLBoniL. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol2015;26:724–730.
MasiGSalvatoreLBoniL. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol2015;26:724–730.
)| false
IwamotoSTakahashiTTamagawaH. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol2015;26:1427–1433.
IwamotoSTakahashiTTamagawaH. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol2015;26:1427–1433.
)| false
CartwrightTHYimYMYuE. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer2012;11:238–246.
CartwrightTHYimYMYuE. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer2012;11:238–246.
)| false
GrotheyAFlickEDCohnAL. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf2014;23:726–734.
GrotheyAFlickEDCohnAL. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf2014;23:726–734.
)| false
GoldsteinDAEl-RayesBF. Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?Oncologist2015;20:981–982.
GoldsteinDAEl-RayesBF. Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?Oncologist2015;20:981–982.
)| false
TaberneroJVan CutsemELakomyR. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer2014;50:320–331.
TaberneroJVan CutsemELakomyR. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer2014;50:320–331.
)| false
FolprechtGPericayCSaundersMP. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol2016;27:1273–1279.
FolprechtGPericayCSaundersMP. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol2016;27:1273–1279.
)| false
TaberneroJYoshinoTCohnAL. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol2015;16:499–508.
TaberneroJYoshinoTCohnAL. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol2015;16:499–508.
)| false
LiJQinSXuR. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2015;16:619–629.
LiJQinSXuR. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2015;16:619–629.
)| false
BelumVRWuSLacoutureME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs2013;31:1078–1086.
BelumVRWuSLacoutureME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs2013;31:1078–1086.
)| false
CutsemEVCiardielloFSeitzJF. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer [abstract]. Ann Oncol2015;26(Suppl 4):Abstract LBA-05.
CutsemEVCiardielloFSeitzJF. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer [abstract]. Ann Oncol2015;26(Suppl 4):Abstract LBA-05.
)| false
AdenisAde la FouchardiereCPauleB. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer2016;16:412.
AdenisAde la FouchardiereCPauleB. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer2016;16:412.
)| false
BendellJCRosenLSMayerRJ. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol2015;76:925–932.
BendellJCRosenLSMayerRJ. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol2015;76:925–932.
)| false
YoshinoTUetakeHFujitaN. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study. Clin Colorectal Cancer2016;15:e205–211.
YoshinoTUetakeHFujitaN. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study. Clin Colorectal Cancer2016;15:e205–211.
)| false
LochheadPKuchibaAImamuraY. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst2013;105:1151–1156.
LochheadPKuchibaAImamuraY. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst2013;105:1151–1156.
)| false
VenderboschSNagtegaalIDMaughanTS. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res2014;20:5322–5330.
VenderboschSNagtegaalIDMaughanTS. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res2014;20:5322–5330.
)| false
OvermanMJKopetzSMcDermottRS. Nivolumab {+/–} ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3501.
OvermanMJKopetzSMcDermottRS. Nivolumab {+/–} ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. J Clin Oncol2016;34(Suppl):Abstract 3501.
)| false
SulJBlumenthalGMJiangX. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist2016;21:643–650.
SulJBlumenthalGMJiangX. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist2016;21:643–650.
)| false
LewisC. Programmed death-1 inhibition in cancer with a focus on non-small cell lung cancer: rationale, nursing implications, and patient management strategies. Clin J Oncol Nurs2016;20:319–326.
LewisC. Programmed death-1 inhibition in cancer with a focus on non-small cell lung cancer: rationale, nursing implications, and patient management strategies. Clin J Oncol Nurs2016;20:319–326.
)| false
NaidooJWangXWooKM. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[published online ahead of print September 19 2016]. J Clin Oncolpii: JCO682005.
NaidooJWangXWooKM. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[published online ahead of print September 19, 2016]. J Clin Oncol, pii: JCO682005.
)| false
HechtJRCohnADakhilS. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line rreatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer2015;14:72–80.
HechtJRCohnADakhilS. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line rreatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer2015;14:72–80.
)| false
